SCHEMBL21290591

SCHEMBL21290591

C=C(C)c1ccc2cc(C(=O)O)ccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.47
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B14 Q9BPX1 2/20 0.44
KDM4E B2RXH2 6/20 0.44
HSP90AA1 P07900 1/20 0.43
ESR2 Q92731 1/20 0.43
MGAM O43451 2/20 0.42
GAA P10253 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
RARA P10276 1/20 0.40
RARB P10826 1/20 0.40
RARG P13631 1/20 0.40
CNR2 P34972 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1644188 0.89 CYP2A6 (0.46) NPC1RAB9AMEN1KMT2AHSD17B14
SCHEMBL69982 0.84 MGAM (0.58) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL264131 0.83 HTT (0.55) NPC1RAB9AMEN1KMT2AHSD17B14
SCHEMBL15484343 0.83 MGAM (0.56) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL1668204 0.80 TDP1 (0.46) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL4302176 0.80 MGAM (0.53) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL27960111 0.76 TDP1 (0.49) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL30464299 0.76 TDP1 (0.58) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL999160 0.76 TDP1 (0.58) TDP1NPC1RAB9AMEN1KMT2A
SCHEMBL264132 0.75 TDP1 (0.49) TDP1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019160813-A1 ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2019-08-22 WO disclosed